Zolmitriptan

• UNSPSC Description:

  Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine[1][2].

• Target Antigen:

  5-HT Receptor; Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Zolmitriptan.html

• Purity:

  99.98

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1OC[C@H](CC2=CC3=C(NC=C3CCN(C)C)C=C2)N1

• Molecular Weight:

  287.36

• References & Citations:

  [1]G R Martin, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997 May;121(2):157-64.|[2]Katherine C Murray, et al. Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol. 2011 Aug;106(2):925-43.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  139264-17-8